Loading…
MicroPort Group unit making stent grafts and devices for treating aortic and peripheral vascular disease.
MicroPort Group unit making stent grafts and devices for treating aortic and peripheral vascular disease.
Sells devices to hospitals, mostly through distributors, and surgeons' training on each device drives repeat use. State-run bulk-purchase schemes have pushed down prices in other implant categories. It is part of the MicroPort group and is listed separately.
In one line: A Chinese Medtronic Endovascular/Gore Aortic.
Moat: narrow (IP / patents, regulatory licence). Device approvals and physician training favor an established device maker.
Headquarters: Shanghai, China · Employees: 822
Size Shanghai MicroPort Endovascular MedTech (688016.SS) is a China Health Care company (Medical Specialties) with a market value of $1.59B, the 1547th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥87.78 on 6 Nov 2026.
Performance Over six months the shares fell 14.2%, against +2.8% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +6.6%); the operating margin is 44.2% (peer median 11.8%).
Valuation It trades at 17.2× forward earnings against a peer median of 22.7× (5th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.9 points above its cost of capital (7.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.45B | CN¥1.34B | CN¥1.20B | CN¥1.18B | CN¥889M |
| Revenue growth | — | +12% | +2% | +32% | — |
| Gross profit | CN¥1.11B | CN¥908M | CN¥844M | CN¥882M | CN¥651M |
| EBITDA | n/a | CN¥665M | CN¥578M | CN¥578M | CN¥417M |
| Net income | CN¥583M | CN¥563M | CN¥502M | CN¥492M | CN¥357M |
| Free cash flow | CN¥254M | CN¥286M | CN¥191M | CN¥381M | CN¥53.2M |
| Capital expenditure | CN¥249M | CN¥303M | CN¥213M | CN¥190M | CN¥294M |
| Total debt | CN¥14.0M | CN¥15.0M | CN¥40.9M | CN¥35.7M | CN¥41.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai MicroPort Endovascular MedTech 688016.SS | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Terumo 4543.T | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688016.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.0% | +0.3% | 8th highest of 21 |
| 6-month return | -14.2% | +2.8% | 4th lowest of 20 |
| Distance from 52-week high | -24.3% | -21.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +16.2% | +6.6% | 8th highest of 21 |
| Operating margin | 44.2% | 11.8% | 2nd highest of 21 |
| Forward P/E | 17.2× | 22.7× | 5th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 3.1% | 18.0% | 4th least demanding of 15 |
| Growth delivered (Del g) | +23.4% | +11.3% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | -20.3 pp | +0.3 pp | least demanding of 15 |
| ROIC minus cost of capital | +16.9 pp | +2.3 pp | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |